An interventional study of The MENTINA app and Control in Depression - Major Depressive Disorder and Mental Distress, sponsored by Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital. Enrolling by invitation at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 124 studies in Depression with a site in Denmark — 14 open to participants now, 17 under way, none of them phase 3. Depression · Denmark.
Among the 124 studies in Depression with a site in Denmark, this one is the 10th largest by planned enrollment of the 92 interventional ones that give a count, is one of 12 that started in 2025, is one of 69 with no phase, reaches primary completion later than 10 of the 16 other live ones, and was the 116th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →14 of the 124 studies in Depression with a site in Denmark are open now. Recruiting first, the newest first:
Aalborg University Hospital · Sites in Denmark
Ages 18–65
Zealand University Hospital · Sites in Denmark
Ages 18+
Nordsjaellands Hospital · Sites in Denmark
Ages 18–65
Aalborg University Hospital · Sites in Denmark
Ages 18–65
University of Southern Denmark · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
124 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 7 · Phase 4 9
First in 2003; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 660 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 139 across the 92 interventional studies, 136 across the 32 observational. Of the 91 that completed or were terminated, 5 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 124 have an industry lead sponsor. The 10 most frequent:
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital is the lead sponsor of 19 studies on the registry; 7 are open to participants now.
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital has 5 studies filed under Depression — fewer than ten, so there is no comparison to draw.
7 of the studies in Depression with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07180407Zealand University HospitalThe Post-ICU Pain Study | 2027-01 |
| NCT06782724University Medical Center GroningenPsilocybin Therapy for Psychological Distress in Palliative Patients | 2027-01-01 |
| NCT06919133Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg HospitalThe Effect of Digital Markers in the Self-management of Depressive Symptoms | 2027-05-01 |
| NCT07080723Aalborg University HospitalAlgorithm Guided Treatment Versus Treatment as Usual (TAU) for Patients With Treatment Resistant Depression | 2027-06 |
| NCT06097221University Hospital Bispebjerg and FrederiksbergThe Advance Project - Advancing Sleep Timing to Improve Depression | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 124 studies in Depression with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the MENTINA trial is to investigate the effect of using the smartphone-based MENTINA app for self-monitoring of depressive symptoms and rule-based feedback in individuals with current or previous depression, psychological vulnerability, and increased risk of depression in a randomized controlled trial (RCT) over a 12-month trial period. The aim is to potentially offer the MENTINA app as a self-management tool for individuals with psychological vulnerability and/or depressive symptoms or episodes.
Method and Design:
International, multicenter (three centers), parallel-group, RCT. The active group is assigned the smartphone-based MENTINA app including rule-based data feedback. The control group uses the MENTINA app for questionnaire-based data collection (outcomes) and collection of sensor-based data.
Study Procedures:
The trial will be open-label and unblinded. The trial uses the self-reported Patient Health Questionnaire-9 score (PHQ-9) as the primary outcome measure. Scoring will take place every 14 days over the 12-month trial period. Depressive symptoms during the first 6 months of app use will also be evaluated as secondary outcomes.
Participants, Including Inclusion and Exclusion Criteria A total of 220 individuals will be included from each center (Denmark, Germany, and Spain) with psychological vulnerability (depressive symptoms and possibly previous depressive episodes). A total sample size of 660 participants will be included.
Inclusion criteria:
Exclusion criteria:
Side Effects, Risks, and Disadvantages
Side effects and risks:
We do not expect any serious side effects from using the MENTINA app. Possible side effects could include increased focus on one's own illness, potentially worsening depressive symptoms and suicidal thoughts.
Recruitment of Participants The study population will consist of adults vulnerable to mental health issues, defined by a PHQ-9 score > 8 or previous depressive symptoms at the time of inclusion. Each study site will be responsible for local recruitment and follow-up.
The intervention in the MENTINA trial consist of a smartphone app, which allows for daily monitoirng of symptoms such as mood, sleep, activity etc. Also, a library with content concerning depressive symptoms will be available.
Rules for feedback based of self-reported measures will be developed. Based on the self-reported measures participants will be suggested to read items from the library or call emergency health care facilities.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The smartphone-based MENTINA app for daily self-monitoring of depressive symptoms and other symptoms + rule-based feedback based on self-monitoried data and sensor data from smartphones
Device: The MENTINA app
The app is installed for outcome measures, but no access to the content of the app is provided.
Other: Control
A smartphone-based app is developed and used in this trial. The smartphone-based MENTINA app allows for daily self-monitoring of depressive symptoms such as mood, sleep, activity etc and rule-based feedback based on self-monitored data as well as collected sensor data. Libary with relevant content will also be available and incoorporated in the rule-based feedback.
The MENTINA app is installed but no content and self-monitoring is available. No rule-based feedback. Only outcome measures can be done.
Patient Health Questionnaire 9 items (PHQ-9)
Differences between the intervention group and the control group in the total Patient Health Questionnaire 9 items (PHQ-9) score performed every 14th day during the 12-months trial period.
Time frame: From enrollment and during the study period of 12 months
Quality of Life
Differences between the intervention group and the control group in the level of quality of life according to the WHO Quality of life BREF16 (WHO QoL)
Time frame: From enrollmetn to end of treatment af 12 months
Generalized Anxiety Disorder 7 items scale (GAD-7)
Differences between the intervention group and the control group in the level of anxiety symptoms according to the Generalized Anxiety Disorder scale (GAD-7)
Time frame: From enrollment to end of treatment at 12 months
PHQ-9
* Monthly change in PHQ-9 scores * Response rate defined as the proportion of participants with ≥50% reduction in PHQ-9 * Remission rate defined as PHQ-9 ≤9 and ≥5-point improvement * PHQ-9 scores at 6 months * Area Under the Curve (AUC) for PHQ-9 over the trial period * Subgroup analysis: differences between the two groups in PHQ-9 analyzed separately for: * People with mental distress (without lifetime depression) * People with a lifetime diagnosis of depression
Time frame: From baseline and during the 12 months study period
Perceived Stress Scale (PSS)
Differences between the group
Time frame: From baseline and during the 12 months study period
User-reported healthcare contacts
Number of healthcare contact during the study
Time frame: From baseline and during the 12 months study period
Negative effects: Negative Effects Questionnaire (NEQ)
Differences between the two groups
Time frame: Form baseline and during the 12 months study period
PHQ-9
* Number of depressive episodes (based on PHQ-9) * Duration * Number of depression-free days (based on PHQ-9)
Time frame: From baseline and during the 12 months study period
Usability of the app: System Usability Scale (SUS)
Usability of the app: System Usability Scale (SUS)
Time frame: From baseline and during the study period
Perceived usefulness for patient-clinician communication
Qualitative interviews
Time frame: From baseline and during the trial period
Interviews with participants and clinicians/psychotherapists
Qualitative interviews on an subsample
Time frame: From baseline and during the trial period
Plan to share: No — Sensitive data that cannot be anonymised completely.
Started May 2025 (actual). Primary completion is estimated for May 2027, 23 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 23 months is close to that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital